兆易創新(603986.SH):使用募集資金對上海思立微增資1億元 實施募投項目14nm工藝嵌入式異構AI推理信號處理器芯片研發項目
格隆匯 8 月 25日丨兆易創新(603986.SH)公佈,為落實公司2019年重大資產重組相關後續事項,公司第三屆董事會第十七次會議審議通過了《關於使用募集資金對全資子公司增資的議案》,決定使用公司2019年重大資產重組配套融資募集資金對募投項目實施主體上海思立微進行增資,增資金額為1億元,用於實施募投項目之14nm工藝嵌入式異構AI推理信號處理器芯片研發項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.